NZ247062A - Method for bovine nuclear transfer - Google Patents

Method for bovine nuclear transfer

Info

Publication number
NZ247062A
NZ247062A NZ24706293A NZ24706293A NZ247062A NZ 247062 A NZ247062 A NZ 247062A NZ 24706293 A NZ24706293 A NZ 24706293A NZ 24706293 A NZ24706293 A NZ 24706293A NZ 247062 A NZ247062 A NZ 247062A
Authority
NZ
New Zealand
Prior art keywords
oocytes
hours
oocyte
conducted
embryo
Prior art date
Application number
NZ24706293A
Inventor
Steven L Stice
Original Assignee
Grace W R & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grace W R & Co filed Critical Grace W R & Co
Publication of NZ247062A publication Critical patent/NZ247062A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0608Germ cells
    • C12N5/0609Oocytes, oogonia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/31Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00Cells related to new breeds of animals
    • C12N2517/10Conditioning of cells for in vitro fecondation or nuclear transfer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Description

New Zealand Paient Spedficaiion for Paient Number £47062 24 7 0 6 2 Priority Date(s): . • Cuiiv'tite Specification Filed: Class: f-.t2.VA *;U>W VAflB..
Vt.3 : S3., Publication Date: ... 2.U.UL p.O. Journal, No: .... Sr1" *r.. .1995....
MO n* aimmac «»W Wi trt/VjAUO •- P^T!T7r7~r — ' L-'-rf - 1333 / RBCP ' • --I No.: Date: NEW ZEALAND PATENTS ACT, 1953 COMPLETE SPECIFICATION IMPROVED PROCEDURE FOR BOVINE NUCLEAR TRANSFER We, W. R. GRACE & CO.-CONN., a corporation of the State of Connecticut, United States of America, 1114 Avenue of the Americas, New York, NY 10036, United States of America hereby declare the invention for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:- - 1 -(followed by page -la-) la Field of the Invention The present invention is generally directed to a process for multiplying bovine embryos, and is specifically directed to an improved process for maturation of the recipient oocyte so that the overall efficiency of the bovine embryo multiplication process is improved.
Background of the Invention Embryo multiplication by nuclear transfer involves the transplantation of the living nuclei from embryonic cells into recipient cells, typically unfertilized eggs. Such transfers are made in order to increase the number of genetically identical embryos which can be obtained from a donor embryo. Once a fertilized embryo has reached a cleavage stage of having at least two cells, it becomes practical to transfer the nuclei from such cells, or the entire cells themselves, into recipient oocytes which have been enucleated, to thereby create multiple genetically identical embryos from such fusions. By allowing each of the fused nuclear transfer embryos to develop to a multiple cell stage, and then repeating the nuclear transplantation procedure, large numbers of geneticaliy identical nuclear transf er »:inbryos oin b<; crcaLod f rom an 'I'iimr <:inl>ryo.
A limitation on the commercial use ol" this process as practj cod to date arises from the fact: (.fiat there arc i.'tU'Lciin inefficiencies in the process as currently practiced. Not all of the nuclear fusions created result in viable embryos. Not all viable embryos created by nuclear fusion turn out to be capable of creating a viable pregnancy in the cow resulting in a live calf.
Accordingly, effort is currently being directed toward optimizing the efficiencies at each step in the procedure, so as to make the overall procedure more economically practical.
The techniques of bovine nuclear transplantation are generally described in two U.S. patents, U.S. Patent No. 4,994,384 and Patent No. 5,057,420, both of which describe procedures for the serial multiplication of bovine embryos. In the techniques described in each of those patents, oocytes are recovered from the ovaries or reproductive tract of cows. The oocytes are selected for proper stage, and then are enucleated by physical aspiration through a transfer pipette, leaving an enucleated oocyte which still retains its external membranes. Synchronously, a donor embryo of the proper cell staging, typically a cleavage or morulae stage, is manipulated so that one or more cells or blastomeres are removed from the embryo. The donor cell which, of course, includes its nucleus, is then inserted into the perivitelline space of the recipient oocyte. An electrical pulse is then applied to fuse the membranes of the donor cell and the recipient oocyte to thus create an activated, fused single cell embryo. That single cell nuclear transfer embryo can then be cultured either in vitro, or in the oviduct of a mammal, until a stage in which it can be implanted into a recipient cow. A significant number of the fused embryos will retain viability, can be transplanted surgically or non-surgically into the uteri of cattle, and will result in a live birth of genetically identical calves.
In a mammal in vivo, ovaries and the embryonic cells contained within them are maintained at physioJogicaJ (around VJ°C) temperatures. Heretofore, it. has boon the custom t.o maintain t ho excised ovaries and embryos withii. the::i at. physiological temperatures throughout the nuclear transp1 ant at ion process, or. the theory t. lt.it such temperatures more closely approximate physiological conditions naturally encountered by the embryos, and thus more closely mimic natural conditions.
Summary of the Invention The present invention is summarized in that a process for bovine nuclear transplantation makes use of recipient oocytes that have been activated before nuclear fusion. Activation results in a higher level of viability of fused embryos created by the process.
In a preferred embodiment, recipient oocytes may be activated by a period of cold culture prior to transplantation of the donor nucleus or cell. Such a cold culture can be conducted at room temperatures (less than 30°C), which is cold only relative to physiological temperatures at which such cultures are normally conducted. In a second embodiment, natural oocyte fertilization by sperm followed by enucleation and nuclear transfer also activates recipient oocytes and increases fusion embryo viability. Other pre-fusion oocyte activation methods are also envisioned.
It is an object of the present invention to further develop and define a step in a bovine nuclear transplantation process so as to increase the overall efficiency of the process.
It is a feature of the present invention in that it is relatively easy to perform, since it requires that recipient embryos be cultured at room temperatures or in the presence of an activating agent, such culture conditions being relatively easy to maintain.
It is an objective of the present invention to aid in the overall efficiency of bovine transplantation and multiplication processes, so as to result in greater numbers of viable pregnancies and multiplied genetically identical calves. .. .1- 24 7 0 6 2 Othi'r objects, ndvantaqos, and features of the pt-osont invention will become apparent from the? following speci1 icaLion .
Description of the Invention In accordance with the present invention, bovine oocytes destined to be the recipient of a nuclear transfer procedure are subjected to an activation step prior to nuclear transplantation procedure. When an activated oocyte is utilized for a nuclear transplantation procedure, the resulting nuclear transfer embryo will be found to be significantly more viable, and more likely to result in a viable pregnancy and a calf, than comparable embryos resulting from oocytes which have not been subjected to an activation procedure.
Activation is most preferably done by culturing the recipient oocyte at a reduced sub-physiological temperature, in essence applying a cold, or actually cool, temperature shock to the oocyte. This may be most conveniently done by culturing the oocyte at room temperatures, which is cold relative to the physiological temperature conditions to which oocytes are normally exposed. This is the most preferred activation protocol because it involves no apparatus and no additions to the culture medium. While cold culture shock activation is a convenient way to practice the invention, the invention is not limited to activation by cold culture. Rather, activation may be achieved, for example, using a host of activation agents. Penetration of the oocyte by sperm during fertilization is also herein shown to activate pre-fusion oocytes which yield greater numbers of viable pregnancies and multiplied genetically identical calves after nuclear transfer. Other treatments, such as electrical shock and chemical shock, may also activate recipient oocytes for nuclear fusion.
The activated oocytes for use within the present invention are intended for a protocol of bovine embryo multiplication through nuclear transplant. It is appropriate therefore, at. this juncture, to brief J y r\ describe the overall bovine embryo mul tipl i cation ^ procedure, Bovine ovaries are collected at the slaughterhouse, and maintained in physiological saline tor transportation from the slaughterhouse to the laboratory. Follicles ranging in size from 2 to 10 nun in diameter are then aspirated from the bovine ovaries. The immature oocytes contained within the follicular fluid are removed, HEPES buffered, and washed in hamster embryo culture medium (HECM) (described in Seshagire et al. , Biol. Reprod., 40, pp. 599-606 (1989), and then placed into drops of maturation medium consisting of 50 microliters of tissue culture medium (TCM) 199 containing 10% fetal calf serum with appropriate gonadotropins luteinizing hormone (LH) and/or follicle stimulating hormone (FSH), and estradiol under a layer of lightweight paraffin or silicon at 39°C. After twenty hours in the maturation media, the oocytes are removed and placed in HECM containing 1 milligram per milliliter of hyaluronidase. The cumulus cells are removed from the oocytes by repeated pipetting through very fine bore pipettes. The stripped oocytes are screened for polar bodies, and the selected metaphase II oocytes, as determined by the presence of the polar bodies, are then used further in the transplantation and multiplication procedures.
The oocyte enucleation portion of the cloning procedure is described in U.S. Patent No. 4,994,384, the specification of which is hereby incorporated by reference. Briefly, the metaphase II oocytes are either placed in HECM containing 7.5 micrograms per milliliter cytochalasin B for immediate enucleation or are placed in CRlaa (described below), plus 10% estrus cow serum, and are enucleated later, preferably sixteen to eighteen hours later. Enucleation is accomplished using a micropipette to remove the polar body and the surrounding cytoplasm. The oocyte can then be screened to determine which oocytes have been successfully enucleated. This screening is successfully done by staining the oocytes with 1 microgram per milliliter 3334 2 Hoechst dye in HECM, and then viewing the oocytes under ultraviolet; irradiation for Jess than 10 seconds . The oocyl.es th.it have? been successfully i'iuic 1 oated can t.hon be placed in culture media, preferably CiUaa plus 10% estrus cow seruin.
After enucleation, a blastomere from a ^reimplantation donor embryo is placed in the perivitelline space, by the method also described in the above-identified Patent No. 4,994,384. For in vitro matured oocytes, this process is normally performed between 36 and 46 hours after the oocyte was first placed in the maturation media. After the blastomere cell is transferred into the perivitelline space of the recipient oocyte, the two cells are fused together by electrofusion. The cells to be fused are placed between two electrodes which are 500 microns apart, referred to as the fusion chamber, which contain Zimmerman's fusion medium. Up until the point of fusion, in previous techniques, the donor cells and the recipient cells have been maintained at 39°C, a physiological temperature. After fusion, the nuclear transfer embryos thus created are then placed in CRlaa plus 10% estrus cow serum at 39°C for 5 to 9 days. A detailed description of a process for culturing in vitro such nuclear transfer embryos can be found in published PCT patent application W0 90/13627. At the end of this culture period, the embryos can be judged for developmental rates. The embryos judged to have developed normally, either into morulae or blastocysts, can be transferred into recipient animals, and an offspring may be obtained after a normal pregnancy.
The above brief description of the embryo multiplication and nuclear transplant process has been altered in the inventive method described herein only prior to the cell fusion step. It has been found that activation of the oocytes during the maturation period increases developmental rates in the resulting nuclear transfer embryos. The oocytes may be cultured in CRlaa medium plus 10% estrus cow serum, just as has been done with the above procedure absent activation.
Cold culture of th<2 oocytes may be done at any temperature significantly below physiological temperatures 247062 (below ;H) "O and above freezing, preferably in the range n! 24°C to 26°C. Even a brief period of cold culture (approx. 2 liours) just: prior to fusion has proven useful in increasing the viability of the nuclear transfer ombryo. A period of cold culture extending over a longer period (20-24 hours) has proven at least egually effective in increasing the survival and viability of the nuclear transfer embryos. The period of cold culture activation can be continuous, but it has also been found that two separated cold culture episodes, at the beginning and end of the in vitro oocyte maturation process, also increases survival and viability.
CRlaa embryo culture medium is described in the following Table 1.
TABLE 1 CR1AA EMBRYO CULTURE MEDIUM NaCl 114 mM KC1 3.1 mM NaHC03 mM Sodium pyruvate 0.4 mM Hemicalcium lactate mM Glutamine 1 mM MEM amino acids 1 ml/lOOml BME amino acids 2 ml/lOOml Gentamicin 50 jig/ml Estrus Cow Serum (ECS) % Oocytes may also be activated by sperm during fertilization in vitro by culture in fertilization medium containing sperm for a period of time sufficient to allow the sperm to penetrate the oocytes. Preferably, the oocytes are fertilized by exposure to sperm at 20 hours after metaphase II selection, and the pronuclei are removed at 39 hours. The pronuclei of recently fertilized oocytes may be revealed using Hoechst dye 33342. Preferably, only those activated oocytes having two pronuclei are enucleated and used as recipient oocytes in the nuclear transfer proper-;*-: described above. 14 Ot.hor act. i v.i t. i on tochniquos may be? usod .is woll, i in" 1 iui i ihi oleot.ric shock and choiuical t.roat.mont. What: i now to the process here is the performance ot activation separate and prior to t.ho step ot. insert ing the donor nucleus. This prior activation enhances the overall oificiencv of the process.
The examples below demonstrate the utility of an activation step and the protocol-independent nature of the activation step. As set forth below, the increase in development after nuclear transfer into activated oocytes can readily be ascertained by parallel experiments in which oocytes are prepared with or without a pre-fusion activation step. Furthermore, the efficacy of various activation steps may be compared by parallel activation steps followed by nuclear transfer.
Examples Cold Culture Activation In the cold culture examples described here, the embryo multiplication procedure described above was repeated with multiple groups of oocytes which had been cultured in differing conditions as described below. In all of these examples, the oocytes removed from the follicles were matured in vitro first for 20-24 hours prior to selection of the oocytes for metaphase II staging. The selected metaphase II oocytes were then cultured (or matured) for an additional 14-24 hour period either at physiological temperatures (about 39°C) or at room temperature (23-26°C), or combinations thereof. All nuclear transfers were performed using entire blastomere cells. The nuclear transfer embryos were either cultured in vitro or in ligated sheep oviducts prior to screening for morula or blastocyst development.
Shown in Table 2 below are the summarized results of a series of replicates in which either or both of the donor blastomeres and the recipient oocytes were cultured at physiological temperatures (designated 39C) or under cold culture of 23-26°C (designated CS). These results df.-rnonstrat.<; ari incroaned rot.'- of nuclear transfer <;mbryo n 7 r development lor a cold culture oocyte, but no effect Lor'a cold cultured donor cell.
TABLE 2 Treatment 3 9C oocyte and 39C donor cell 39C oocyte and CS donor cell CS oocyte and CS donor cell No. Recovered No. Developed Percent From Culture to Morulae or Developed Blastocyst 199 169 237 9 3 42 % 2* 18% To verify that this statistically significant result was principally due to the cold culture of the recipient oocyte rather than the donor cell, the experiment was replicated using all four possible temperature permutations, and the data is summarized in the following Table 3.
TABLE 3 Treatment No. Recovered No. Developed Percent From Culture to Morulae or Developed Blastocyst 39C oocyte and 80 1 1% 39C donor cell 39C oocyte and 131 8 7% CS donor cell CS oocyte and 44 5 11% 39C donor cell CS oocyte and 134 19 14% CS donor cell A comparison of the first and third conditions above indicates clearly that the room temperature culture of the recipient oocytes is the biggest factor in efficiency improvement. The difference between conditions three and four is not considered significant.
Several replicates were conducted t.o compare the timing of the cold culture.' period. A cold culture period nt .'0-27 hours after metaphase II selection and prior to ir.mslor and fusion was the best oi the conditions tested. A cold culture period limited to two hours after the selection of metaphase II oocytes proved of limited improvement, but a regimen of two hours of cold culture (25°C) followed by sixteen hours of physiological culture (39°C) and two additional hours of cold culture (25°C) was of greater improvement. Slight timing change, such as 3 hours rather than 2 hour cold culture, or 22 hours as compared to 20 hours, seemed to make little significant di f ference.
These results demonstrate a clearly discernible trend toward increased nuclear transfer embryo viability and survival when the recipient oocyte has received a cold culture treatment for a time period in excess of 2 hours and within 24-48 hours prior to cell fusion. This cold culture is believed to serve as a form of pre-fusion activation of the recipient oocyte. Whatever the cause of the phenomenon, it can be used to increase the efficiency of a practical bovine embryo multiplication protocol.
Fertilization activation In this example, nuclear transfer into enucleated oocytes after in vitro activation by natural oocyte fertilization was compared against nuclear transfer after cold culture activation. One population of pre-fusion oocytes were activated by cold culture at 23-27 °C for three hours before enucleation, while a second group of oocytes were activated by sperm penetration according to the following protocol. At 20 hours after metaphase II selection, the second group of oocytes were placed in fertilization medium and were exposed to sperm for approximately 18 hours, at which time the fertilized oocytes contained pronuclei that were roughly 25 iim in diameter. The fertilized oocytes were enucleated with the aid of Hoechst dye 33342. Only oocytes which had two pronuclei and which could be enucleated were used as recipient oocytes.
Both sets ot enucleated oocytes were used as recipients in the nuclear transfer protocol described above. As shown in Table 4, sixteen percent ot the nuclear transfer embryos derived from fertilized oocytes matured to the morula and blastocyst stage. This rate did not differ significantly from the twenty two percent development rate obtained using cold cultured oocytes.
The data of this example demonstrate that activation of a recipient oocyte may be achieved using natural sperm fertilization and with cold culture. As such, activation before fusion appears to be a generally advantageous step in the preparation of recipient oocytes in a nuclear transfer protocol, without regard to the activation method chosen.
TABLE 4 Activation protocol No. of Nuclear Transfers Development to Morula and Blastocyst (Percent Development) Cold Culture 112 (22%) Fertilization 80 13 (16%) 247062 1. A method of preparing recipient bovine oocytes Lor a nuclear transfer process comprising the steps of (a) recovering ovaries from cows; (b) isolating immature oocytes from the ovaries; (c) maturing the oocytes in the presence of gonadotrophins at a physiological temperature; (d) selecting among the matured oocytes for metaphase II oocytes; (e) enucleating the activated oocytes; and (f) activating the selected oocytes.

Claims (18)

  1. WHAT WE CLAIM IS:
  2. 2. A method as claimed in claim 1 wherein the maturation step (c) is conducted for 20-24 hours.
  3. 3. A method as claimed in claim 1 wherein the selection step (d) is performed by examining for the presence of polar bodies.
  4. 4. A method as claimed in claim 1 wherein the activating step (f) is by a cold culture for a time period in excess of 2 hours and at a temperature less than 30°C.
  5. 5. A method as claimed in claim 4 wherein the activating step (f) is conducted at a room temperature of between 23° and 26°C.
  6. 6. A method as claimed in claim 4 wherein the activating step (f) is conducted for a time period of at least 20 hours. -13- 24 7 0
  7. 7. A method as claimed in claim 1 wherein the activating step (f) is by fertilization in the presence of s pe rm.
  8. 8. A method as claimed in claim 1 wherein the activating step (f) is conducted for a time period of about 18 hours.
  9. 9. A method of producing a multiplied bovine embryo comprising the steps of (a) isolating a recipient oocyte; (b) enucleating the recipient oocyte; (c) activating the recipient oocyte; (d) isolating a donor blastomere cell from a donor embryo; (e) introducing the donor blastomere cell into the perivitelline space of the recipient oocyte; (f) fusing the donor blastomere cell into the recipient oocyte to make a nuclear transfer embryo; and (g) transferring the nuclear transfer embryo into a maternal animal.
  10. 10. A method as claimed in claim 9 wherein after the isolating step (a), the oocyte is matured in the presence of gonadotrophins prior to the activation step.
  11. 11. A method as claimed in claim 7 wherein after the isolating step (a) and the maturing in the presence of gonadotrophins, the oocytes are selected for metaphase II condition. - H- 2^7062
  12. 12. A method as claimed in claim wherein the .ict. i vat: inq sti?p (c) is by cold culture for a time period in excess of 2 hours and at a temperature of less than
  13. 13. A method as claimed in claim 12 wherein the activating step (c) is conducted at a room temperature of between 23° and 26°C.
  14. 14. A method as claimed in claim 12 wherein the activating step (c) is conducted for a time period of at least 20 hours.
  15. 15. A method as claimed in claim 9 wherein the activating step (c) is by fertilization in the presence of sperm.
  16. 16. A method as claimed in claim 9 wherein the activating step (c) is conducted for a time period of about 18 hours.
  17. 17. A method of preparing recipient bovine oocytes for a nuclear transfer process as claimed in any one of claims 1 to H substantially as hereinbefore described with reference to the included examples.
  18. 18. A method of producing a multiplied bovine embryo as claimed in any one of claims 9 to 16 substantially as hereinbefore described with reference to the included examples. 3 0°r. By the authorised agenta , J PARK & SON
NZ24706293A 1992-03-04 1993-03-04 Method for bovine nuclear transfer NZ247062A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84618792A 1992-03-04 1992-03-04
US1663693A 1993-02-12 1993-02-12

Publications (1)

Publication Number Publication Date
NZ247062A true NZ247062A (en) 1995-07-26

Family

ID=26688877

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ24706293A NZ247062A (en) 1992-03-04 1993-03-04 Method for bovine nuclear transfer

Country Status (5)

Country Link
EP (1) EP0559307A1 (en)
JP (1) JPH06125772A (en)
AU (1) AU667507B2 (en)
CA (1) CA2091052A1 (en)
NZ (1) NZ247062A (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5480772A (en) 1993-02-03 1996-01-02 Brandeis University In vitro activation of a nucleus
WO1995003398A1 (en) * 1993-07-23 1995-02-02 Monash University Enucleation of oocytes
FR2720407B1 (en) * 1994-05-31 1996-10-11 Gestion Engineering Et Aqueous vehicle for non-autonomous microorganisms of the animal kingdom to be kept alive outside their natural environment, in particular bovine spermatozoa.
US6331659B1 (en) 1998-01-21 2001-12-18 University Of Hawaii Cumulus cells as nuclear donors
AU780366B2 (en) 2000-01-20 2005-03-17 Diatranz Otsuka Limited Preparation and xenotransplantation of porcine islets
US20030113910A1 (en) * 2001-12-18 2003-06-19 Mike Levanduski Pluripotent stem cells derived without the use of embryos or fetal tissue

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994384A (en) * 1986-12-31 1991-02-19 W. R. Grace & Co.-Conn. Multiplying bovine embryos
IL86588A0 (en) * 1987-06-05 1988-11-30 Granada Genetics Inc Bovine nuclear transplantation
IL94184A0 (en) * 1989-05-01 1991-01-31 Granada Biosciences Inc In vitro maturation of bovine oocytes

Also Published As

Publication number Publication date
AU3398193A (en) 1993-09-09
CA2091052A1 (en) 1993-09-05
AU667507B2 (en) 1996-03-28
JPH06125772A (en) 1994-05-10
EP0559307A1 (en) 1993-09-08

Similar Documents

Publication Publication Date Title
JP2882527B2 (en) Bovine embryo propagation method
US5453366A (en) Method of cloning bovine embryos
JP5058166B2 (en) Nuclear transfer
De Sousa et al. Reprogramming of fibroblast nuclei after transfer into bovine oocytes
Heyman et al. Developmental ability of bovine embryos after nuclear transfer based on the nuclear source: in vivo versus in vitro
Deng et al. Full term development of rabbit oocytes fertilized by intracytoplasmic sperm injection
JPWO2007096985A1 (en) Method for producing fish embryo
RU2205536C2 (en) Method for obtaining cloning cows
Ock et al. Different activation treatments for successful development of bovine oocytes following intracytoplasmic sperm injection
NZ247062A (en) Method for bovine nuclear transfer
WO1998029532A1 (en) A method of oocyte enucleation and production of reconstituted embryos
AU2766401A (en) Method for cloning animals with targetted genetic alterations by transfer of long-term cultured male or female somatic cell nuclei, comprising artificially-induced genetic alterations, to enucleated recipient cells
CA2092258A1 (en) Synchronized donor cells for bovine nuclear transfer
Prather et al. Nuclear transplantation as a method of producing genetically identical livestock
US20030217378A1 (en) Cloning using rapidly matured oocytes
Kazemi et al. Royana: successful experience in cloning the sheep
WO2001000794A1 (en) Method for producing cloned tigers by employing inter-species nuclear transplantation technique
EP1071321B1 (en) Source of nuclei for nuclear transfer
WO2002019811A2 (en) Generation of transgenic animals using nuclear transfer and oocytes at the germinal vesicle stage
WO2003005810A9 (en) Cloned non-human mammals from contact inhibited donor cells
WO2002028164A2 (en) Cloning endangered and extinct species
RU2205537C2 (en) Method for obtaining cloned tiger due to applying method of interspecific nuclear transplantation
Gou et al. Transgenic twin lambs cloned by granulosa cells
US20060174358A1 (en) Method for cloning animals with targetted genetic alterations by transfer of long-term cultured male or female somatic cell nuclei, comprising artificially-induced genetic alterations, to enucleated recipient cells
KR101446888B1 (en) Method for oocyte vitrification for somatic cell nuclear transfer and method for production of cloned embryos from somatic cell using the same